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The eosinophil was first named by the bril-
liant German scientist Paul Ehrlich in 1879,
while he was experimenting with aniline
dyes to stain blood cells and tissues. He
also discovered neutrophils, basophils, and
mast cells. The highly basic proteins in
cytosolic granules of a small subpopulation
of cells in human blood stained vivid pink
with the acid dye eosin (from the Greek
“eos” meaning dawn), hence “eosinophils.”
He subsequently observed high numbers
of these cells in the sputum of asthmatic
patients and recognized the close relation-
ship between eosinophilia and the sever-
ity of asthma. Pertinent to our story was
his proposition that a “material which
attracts eosinophils”exists. Further, he pos-
tulated that eosinophils and neutrophils
possess different “chemotactic irritability”
and that eosinophils only migrate to sites
where a “specific stimulating substance” is
present (1).
This could have been the inspiration
behind the Eotaxin project but, in truth,
its origins were more prosaic. To pro-
vide a brief background, my Ph.D. project
on mechanisms of inflammation involved
the measurement of microvascular plasma
protein leakage in rabbit and guinea pig
skin using 125I-albumin as a marker. This
led to an investigation of endogenous
mediators that increase the permeabil-
ity of venules in vivo using intradermal
zymosan as the inflammatory stimulus.
Alternatively, zymosan was administered
intraperitoneally in rabbits and the skin
system was used as an in vivo bioassay for
peritoneal exudates collected at intervals.
The major finding from all these stud-
ies was that the principle permeability-
increasing mediator was extravascularly
generated C5a. Further, C5a-induced leak-
age was dependent on a rapid interaction
between neutrophils and venular endothe-
lial cells, as evidenced by neutrophil deple-
tion experiments (2): (followed up recently
in J Exp Med, 2014). We then began exper-
iments with 111In-neutrophil trafficking
in vivo, and the purification and iden-
tification of C5a brought us into con-
tact with an expert protein sequencing
group in London. In a paper published
in 1986, we noted that there was a small
amount of permeability-increasing activ-
ity, other than C5a, in 2 h zymosan-induced
peritoneal exudates. Some time later, we
assayed 6 h exudates in the skin in the
presence of a C5a neutralizing antibody
and identified two potent activities. Purifi-
cation using HPLC, followed by microse-
quencing, revealed that these were the rab-
bit equivalents of IL-8 (CXCL8) and MGSA
(CXCL1); results published in 1990 and
1991. Thus, at this stage, our journey had
taken us from an interest in the barrier
function of the venular endothelium, to the
complement system and neutrophils, and
then on to chemokines.
By this time, I had moved to the
National Heart & Lung Institute in West
London to take up a professorial chair
funded by a charity, the National Asthma
Campaign, later renamed Asthma UK. We
seemed to be on another planet; clearly,
the world of asthma was orbiting around
the eosinophil. There was little interest in
the neutrophil (although eventually this
changed with a growing emphasis on the
heterogeneity of the disease, some asthma
subtypes being clearly neutrophilic). To
redress the balance, I introduced Lucia Fac-
cioli, a visitor from Brazil, to eosinophil
expert Redwan Moqbel in the Institute
and we developed a method to measure
111In-eosinophil accumulation in guinea
pig skin in vivo. I later recruited David
Griffiths-Johnson who had specialized in
lung lavage of allergen-challenged sensi-
tized guinea pigs. The plan to combine the
two techniques as an in vivo generating and
in vivo bioassay system to identify endoge-
nous eosinophil chemoattractants was sub-
mitted to the asthma charity as a project
grant, but sadly this was rejected with not
unreasonable reservations about feasibil-
ity. Despite this, we continued using funds
raised for another project. After several
“false dawns,” the pursuit proved success-
ful and in 1992 we were regularly detecting
activity in lung lavage fluid, indicated by
a strong 111In-eosinophil signal in bioas-
say skin samples. Unfortunately, at this
point, we had lost our biochemist, Peter
Jose, who had developed the methodol-
ogy for the purification of rabbit IL-8 and
MGSA. Peter had abandoned the hunt for
the elusive eosinophil chemoattractant and
moved out of science to a rural retreat
in Marmande in France. I flew to France
clutching the new data and met Peter who
seemed more interested in the ripening of
his strawberry crop, but was persuaded to
return to London to take on the challenge.
The lavage fluid was put through a series of
HPLC purification stages and within a rela-
tively short time Peter had purified the pro-
tein for microsequencing. Within 2 weeks,
the sequencing group had an N-terminal
sequence of a novel CC chemokine. Soon,
they had sequenced peptide proteolytic
fragments of the protein and had assem-
bled the full 73-aa sequence. We called
this protein “Eotaxin” (condensed from
“eosinophil chemotaxin”). We submitted
a manuscript to Nature and were pleased
with the positive reports that came back
from two of the referees, which betrayed
a North American flavor (“flavor”). The
third, more critical, referee appeared to


























































be from the “United” Kingdom and stated
that the molecule had not been cloned
and that chemotaxis had not been demon-
strated in vitro. These statements were
true, but seemed to miss the point. There
was considerable interest in academia and
industry in the eosinophil as a therapeu-
tic target in asthma. Activated eosinophils
release their highly basic, tissue-damaging
proteins, and a range of mediators that
can exacerbate lung inflammation. Despite
the interest, cloning had not revealed the
Eotaxin sequence. We had tried eosinophil
chemotaxis in vitro as an assay, but the
cells were confused by a whole gamut of
non-specific stimulants in lavage fluid. In
contrast, the in vivo skin assay excelled in
picking up the chemoattractant “needle” in
a “haystack” of irrelevant molecules. After
two more unsuccessful attempts at submis-
sion to Nature with more data, the paper
was redrafted and appeared, considerably
delayed, in the Journal of Experimental
Medicine in March 1994 (3).
In early 1994, I received a phone call
from Tim Springer inviting me to give a talk
at Harvard. After the talk, Tim remarked
that Henry Dale (who deduced that his-
tamine was released in vitro from tissues
of allergen-sensitized guinea pigs in the
early 1900s) would have appreciated our
approach. I took this as a compliment but,
on reflection, this more resembled under-
standable sarcasm at our “retro” method-
ology. However, one advantage with our
approach was that we could immediately
set our molecule in a disease context and
give it a rational name. With the encour-
agement of Craig Gerard, Tim invited me
to join the scientific advisory board of
LeukoSite Inc., the company that he had
recently founded with Eugene Butcher.
The Eotaxin patents were licensed to the
Company and a successful relationship
ensued. Based on the protein sequence
(Figure 1) we cloned guinea pig Eotaxin
in a previously established collaboration
with Christine Power at GSK in Geneva.
Marc Rothenberg at Harvard then used
the guinea pig protein sequence to clone
mouse Eotaxin and embarked on a series of
experiments with allergy models in Eotaxin
knockout mice (4) followed by important
papers demonstrating a role for Eotaxin,
particularly in diseases of the GI tract.
Paul Ponath and colleagues at LeukoSite
cloned human Eotaxin (5) and its recep-
tor CCR3. There were several publications
on these sequences around this time. Sub-
sequent discoveries in other laboratories
published in 1997 and 1999 revealed two
more Eotaxins signaling through CCR3,
Eotaxin-2 (CCL24), and -3 (CCL26), with
low sequence similarity to the renamed
Eotaxin-1, designated CCL11 of the CC
chemokine family. We used immunoassays
to investigate the role of Eotaxin-1 in the
guinea pig allergy model (6), and Alison
Humbles then moved to Craig Gerard’s
laboratory to investigate mouse models
using CCR3 knockout mice. Many groups,
including ours, published papers show-
ing the expression of Eotaxin in human
asthma.
A recurring question from eosinophil
experts concerned the relationship
between Eotaxin and the cytokine, IL-5,
which was reported to be an eosinophil
chemoattractant. Contrary to the reports,
we found that IL-5 did not induce
eosinophil accumulation when injected
into guinea pig skin. However, intravenous
IL-5 induced the release of eosinophils
from the bone marrow reserve and the
dramatic increase in circulating cells in
the blood markedly enhanced eosinophil
recruitment induced by intradermal
Eotaxin-1 (7). We subsequently devel-
oped an in situ bone marrow perfusion
system to study mechanisms of eosinophil
release in detail.
As at LeukoSite, many companies devel-
oped CCR3 antagonists. Ian Sabroe in my
laboratory devised a technique to mea-
sure responses of human eosinophils to
chemokines (the “GAFS” Shape Change
Assay, now widely used in academia and
industry) and discovered a subpopulation
of donors whose cells responded to CCR3
and CCR1 agonists. This led to the first
publication on a CCR3 antagonist (8), one
that could also antagonize CCR1. There
have been clinical trials of CCR3 antago-
nists in asthma patients but, as yet, no drug
has reached the market. Cambridge Anti-
body Technology (now MedImmune) pro-
duced a potent therapeutic antibody (CAT-
213, iCo-008, Bertilimumab) that neutral-
izes Eotaxin-1. This antibody, tested ini-
tially in allergic rhinitis, has been licensed
to iCo Therapeutics and to Immune Phar-
maceuticals, for testing in further clinical
trials. As well as being evaluated as a ther-
apeutic target in asthma and in allergic
diseases in general, Eotaxin-1 is used as a
biomarker in clinical trials. There is also
interest in diseases of the GI tract where
FIGURE 1 | Generation, bioassay, purification, and sequencing of Eotaxin-1.


























































Rothenberg’s work has been particularly
influential, with trials planned in ulcera-
tive colitis and Crohn’s disease. In addition,
Eotaxin-1 is implicated in diseases, such as
atherosclerosis, apparently independently
of its action on eosinophils. Interestingly,
as published in Nature in 2009, CCR3
is expressed on endothelial cells in vessel
overgrowth of the macula in age-related
macular degeneration (AMD) and locally
produced Eotaxins are thought to medi-
ate angiogenesis in this condition [see Ref.
(9)]. Thus, Bertilimumab is being consid-
ered for the treatment of AMD and other
eye diseases. There is also evidence, from
cross-circulation studies between old and
young mice that circulating Eotaxin-1 rises
during aging and this suppresses neuro-
genesis and cognitive function, as pub-
lished in Nature in 2011 [see Ref. (9)],
raising possibilities for future therapy in
dementia.
Thus, from humble origins, the work
on Eotaxin-1 has raised tantalizing oppor-
tunities for therapy ranging across several
diseases. These possibilities have not yet
translated into effective therapy, but we are
not alone in this in the chemokine field (9).
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